RSC Advances



PAPER

View Article Online



Cite this: RSC Adv., 2021, 11, 38283

Fluorescently labeled xylosides offer insight into the biosynthetic pathways of glycosaminoglycans†

Roberto Mastio, ‡ Daniel Willén, ‡ Zackarias Söderlund, © Gunilla Westergren-Thorsson, D b Sophie Manner, Emil Tykesson D and Ulf Ellervik **D ** and Ulf E

Five novel xylosides tagged with the fluorescent probe Pacific Blue™ were synthesized and found to act as substrates for B4GalT7, a bottleneck enzyme in the biosynthetic pathways leading to glycosaminoglycans. By confocal microscopy of A549 cells, we showed that the xylosides were taken up by the cells, but did not enter the Golgi apparatus where most of the glycosaminoglycan biosynthesis occurs. Instead, after a possible double galactosylation by $\beta 4GalT7$ and $\beta 3GalT6$, the biosynthesis was terminated. We hypothesize this is due to the charge of the fluorescent probe, which is required for fluorescent ability and stability under physiological conditions.

Received 20th August 2021 Accepted 22nd November 2021

DOI: 10.1039/d1ra06320k

rsc.li/rsc-advances

Introduction

Proteoglycans (PG) are macromolecules that consist of long, negatively charged, linear carbohydrate chains, i.e. glycosaminoglycans (GAGs), attached to the surface of a core protein. Proteoglycans are mainly located in the extracellular matrix of mammalian cells and are involved in processes such as tissue development, cellular growth, adhesion, and coagulation.1 The GAG chains are composed of alternating disaccharides of (-4) GlcNAc(β 1-4)GlcA(β 1-) for heparan sulfate (HS) or (-3)GalNAc(β 1-4)GlcA(β 1-) for chondroitin sulfate (CS). The growing polymer is concomitantly modified by epimerization of GlcA to IdoA, to form dermatan sulfate (DS) from CS, and sulfation of both the uronic acids and the hexosamines, results in extensive structural diversity. The enzymes of the biosynthetic pathway of GAG synthesis are known and, in many cases, cloned and expressed. However, the organization of these enzymes in the Golgi and ER is known to a much less extent. According to the GAGosome theory, some of these enzymes are co-localized and work synchronously.²

The disaccharide polymer is bridged by a linker region, which for HS and CS/DS consists of a tetrasaccharide motif, i.e. GlcA(β 1-3)Gal(β 1-3)Gal(β 1-4)Xyl β (cf. Fig. 1a). The formation of these GAGs is initiated by xylosylation of a serine residue in the core protein followed by galactosylation of the xyloside moiety by β -1,4-galactosyltransferase 7 (β 4GalT7). Interestingly, xylose is a rather unusual carbohydrate in mammalian cells and thus

It has been known since the 1970s that β-D-xylopyranosides with hydrophobic aglycons can permeate cell membranes and initiate GAG synthesis in competition with the natural PG synthesis (Fig. 1b). Since these GAGs are not connected to a protein core, they are soluble and usually secreted into the extracellular space. The amounts and structure of the primed GAGs are dependent on both aglycon and cell type.2-11

We have earlier presented xylosides with aglycons based on a naphthalene core (e.g. naphthyl β-D-xylopyranoside, XylNap, cf. Fig. 1b) and we have investigated the effects of different xylosides on the GAG fine structure.12-15

The enzymatic mechanism for the first galactosylation step was clarified by cloning and expression of β4GalT7 by Almeida et al. in 1999.16 Later on, the crystal structure of human β4GalT7 was resolved by Qasba and co-workers in 2013 and showed that a conformational change upon binding of UDP or UDP-Gal formed a hydrophobic, xyloside binding, pocket.17 The galactosylation then proceeds with an S_{N2}-like mechanism where the 4-OH of xylose attacks the anomeric position in UDP-Gal with UDP as leaving group. In 2014 we presented a β4GalT7assay and initiated the search for GAG primers.18

To study the biosynthesis, and search for a GAGosome, a fluorescently labeled xyloside that functions as a GAG primer would be highly valuable. 19-21 For this approach to be successful, the xyloside must be able to first permeate through the cell membrane and then be able to initiate GAG-synthesis.

Previous attempts to design fluorescently labeled xylosides are exemplified in Chart 1. Johnsson et al. presented naphthoxylosides fused with anthracene and dansyl groups (1 and 2). These compounds were taken up by the cells but no induction of GAG synthesis could be shown. 11,22 This was then believed to be due to the bulkiness of the dansyl and the (9-anthracenyl)

a potential selective target for intervention of the GAG biosynthesis pathway.

^aCentre for Analysis and Synthesis, Centre for Chemistry and Chemical Engineering, Lund University, P. O. Box 124, SE-221 00 Lund, Sweden. E-mail: ulf.ellervik@ chem.lu.se

^bDepartment of Experimental Medical Science, Lund University, P. O. Box 117, SE-221 00 Lund, Sweden

[†] Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra06320k

[‡] These authors contributed equally to this work.




Fig. 1 (a) Biosynthesis of the linker tetrasaccharide of HS and CS/DS. (b) Priming of GAG synthesis by xylosides is initiated by galactosylation of **XylNap** by β 4GalT7 to form GalXylNap. (c) Concept of this study. Fluorescently labeled xylosides are expected to be taken up by cells and initiate GAG priming to release fluorescently labeled GAG chains.

methyl aglycons. Later, Tran *et al.* synthesized xylosides connected to dansyl and fluorescein groups *via* a triazolyl linkage. Similar to the results of Johnsson *et al.*, these compounds were not able to initiate priming. However, Tran *et al.* did observe GAG synthesis using xylosides carrying umbelliferyl and pyrene groups coupled *via* a triazolyl linkage (3 and 4).²³ While the pyrene analogs could not be detected by fluorescence, the corresponding umbelliferyl analogs were detected and showed longer HS chains compared to the 4-methylumbelliferyl xylosides not carrying a triazolyl linkage. However, since their quantum yields decrease significantly in water, these conjugates are still not optimal for investigations of the GAG biosynthesis.^{24,25}

A coumarin-based fluorophore that has gained popularity in cell biology, due to its small size and high quantum yield, is the 6,8-difluoro-7-hydroxycoumarin-3-carboxylic acid, or Pacific BlueTM (referred to as PacBlue in this article, *cf.* Chart 2).^{26–29} The two fluorine atoms flanking the hydroxyl lowers the pK_a (*i.e.* 3.7, compared to 7.5 of the nonfluorinated coumarin) and it is thus deprotonated at physiological pH, which is important for the fluorescence.³⁰

Chart 1 Examples of earlier attempts to fluorescently labeled GAGpriming xylosides.

Furthermore, synthetic pathways to the coumarin dye have been published^{31,32} enabling multigram synthesis.³³ PacBlue can also be used for FRET (Förster Resonance Energy Transfer) studies with other fluorophores, such as the amino acid tryptophan, enabling studies of ligand–protein interaction in proteins with suitably positioned tryptophan residues within the protein scaffold.³²

We hypothesize that xylosides carrying the PacBlue moiety will be taken up by cells, initiate the GAG biosynthesis and release fluorescently labeled GAGs (Fig. 1c). The ability of PacBlue xylosides to act as a substrate for β 4GalT7 has not been tested before, although other coumarin-containing xylosides (*e.g.* methylumbelliferyl) have been shown to be both inhibitors and substrates for GAG-biosynthesis. The rationale of this paper is to explore the binding efficacy of the xylosides carrying the PacBlue moiety (Chart 2) in the β 4GalT7 assay, as well as to determine cellular uptake and GAG priming ability.

Results and discussion

Synthesis of PacBlue xylosides

Previous results from us and others have shown that the length of the linker between the xylose moiety and the aglycon significantly influences galactosylation by β4GalT7.^{2,21} Therefore, we

Chart 2 . Structures of the investigated xyloside analogs.

decided to synthesize a series of PacBlue xylosides 5-9 (Chart 2) with different linker lengths as well as a dithioxyloside. The later analog has been shown to be a good substrate for β4GalT7.19

Synthesis of targets 5-8 was performed using conventional carbohydrate synthetic methods (Scheme 1a), starting from peracetylated D-xylose (10) and commercially available, suitably protected linkers. Glycosylation using BF₃·OEt₂ in MeCN, with Cbzprotected amino alcohols furbished compounds 11, 14, 17, and 20.

Removal of the Cbz protecting group was performed by hydrogenation (H₂, Pd/C), to give 12, 15, 18, and 21 as the free amines. These intermediates were then subjected to EDC-promoted coupling using HOBt as a catalyst, furbishing 13, 16, 19, and 22. Final deprotection using K₂CO₃ in MeOH gave compounds 5, 6, 7, and 8.

Synthesis of compound 9 required a different strategy (Scheme 1b). Glycosylation was first attempted using the peracetylated thioxyloside in a similar fashion as the other targets with BF₃·OEt₂ as the promoter, without success. Previous glycosylations using this donor, 19,36 have involved aromatic, rather than aliphatic, thiols as acceptors, which could explain the low reactivity. Instead, we used the 2,3,4-tri-O-acetyl-5-thio-α-D-xylopyranosyl bromide³⁷ (23), and ZnO-ZnCl₂ as the promoter system in a MeCN-toluene mixture³⁸ along with a Boc-protected linker. Indeed, the ZnO-ZnCl2 promoter at 60 °C yielded a sufficient amount of 24 as a 2 : 1 β/α mixture. Deacetylation was performed using LiOH in MeOH and Boc deprotection using HCl in EtOH. Amide coupling was performed using the commercial amine-reactive succinimidyl ester of PacBlue to finally yield 9.

Measurement of lipophilicity

The partition coefficients of compounds 5-9, in reference to XylNap, 10 were estimated by gradient HPLC retention times (Table 1).39,40 The dithio-analog 9 showed the most similar lipophilicity compared to XylNap.

Scheme 1 Reagents and conditions (a) (i) Cbz-protected linker, BF₃-·OEt₂, MeCN, MS 3 Å, 2 h, r.t., 14-21%; (ii) Pd/C, H₂, MeOH, 2 h; r.t., 62-100%; (iii) Pacific Blue™ carboxylic acid, EDC, HOBt, TEA, DCM, 2 h; r.t., 36-58%; (iv) K₂CO₃, MeOH, 1 h; r.t. 96-98%. (b) (v) Boc-protected thiol linker, ZnO-ZnCl₂, toluene/MeCN (1:1), MS 3 Å, 60 °C, 2 h; 40%, β/ α 2 : 1; (vi) HCl (1 M), EtOH, 1 h, r.t, 52%; (vii) MeOH, LiOH, 40 min, r.t., 98%, β/α 2 : 1; (viii) Pacific BlueTM succinimidyl ester, DIPEA, DMF, 4 h; r.t. 46%.

Galactosylation by β4GalT7

We have earlier developed an improved enzymatic assay of β4GalT7 substrate activity and/or inhibition.41 Compounds 5-9 were thus evaluated using this assay in regards to galactosylation. All compounds were found to be efficiently galactosylated by β4GalT7 up to a concentration of approximately 0.5 mM, after which a substantial amount of substrate inhibition was observed (Fig. 2 and Table 2). Both the V_{max} (approximately 0.1 pmol s⁻¹) and $K_{\rm m}$ (0.1–0.2 mM) of the XylPacBlue derivatives were significantly higher and lower, respectively, compared to XylNap. The sulfur analog (9) had the fastest kinetics, but no big differences were observed between linker length variants (5-7), nor of the branched-chain variant (8).

We have previously shown that compounds 1 and 2 fail to induce GAG synthesis in human T24 cells. In agreement with those results, we did not observe any galactosylation of these compounds in the β4GalT7 assay (data not shown).

Uptake, priming, and cellular distribution

In order to be used as tools for studying the GAG biosynthesis, we evaluated the ability of the compounds to be taken up and to initiate biosynthesis of GAGs in living cells. Therefore, compounds 5, 7, and 9, and the acetylated form of 7 (i.e. compound 19) were investigated in vitro using A549 cells. Acetylated carbohydrates have a significant increase in uptake




Fig. 2 Michaelis–Menten representation of the activity of β4GalT7 (V) as a function of the concentration of XylNap (stars), 5 (solid circle), 6 (open circle), 7 (solid square), 8 (open square), and 9 (triangle).

Table 1 Retention times of 5-9 compared to XylNap

Compound	Retention time a (min)	
5	9.65 ± 0.01	
6	11.7 ± 0.01	
7	13.8 ± 0.01	
8	13.2 ± 0.01	
9	15.5 ± 0.04	
XylNap	14.9 ± 0.00	

^a Gradient from $5:95 \rightarrow 100:0$ MeCN: water, 1.2% MeCN increase per minute. Retention times are a mean of three measurements.

Table 2 Galactosylation of xylosides by β4GalT7

Compound	<i>K</i> _m , (mM)	$V_{\rm max}$, (pmol s ⁻¹)	$k_{\rm cat}, ({ m s}^{-1})$	$k_{\rm cat}/K_{\rm m}$, (mM ⁻¹ s ⁻¹)
5	0.39	14.1	4.4	11.3
6	0.55	17.0	5.3	9.7
7	0.57	18.9	5.9	10.3
8	0.57	19.0	6.0	10.4
9	2.2	65.8	20.6	9.3
XylNap	0.84	10.0	3.1	3.7




Fig. 3 Reversed-phase chromatography analysis of 5 before (A) and after (B) enzymatic treatment, as well as of ion exchange-purified medium from A549 cells treated with 0.1 mM 5 for 24 h (C).

(up to three orders of magnitude),⁴² and acetylation is a common way of making drugs more permeable across the lipid bilayer, whereupon uptake the esters are cleaved off by nonspecific esterases and reveal the active substrates.⁴³

No priming of full-length GAGs was observed for either of the compounds (ESI Fig. 1†). However, when ion exchange-purified cell medium was analyzed by fluorescence-coupled reversed-phase chromatography, we observed secreted products corresponding to Gal-XylPacBlue, confirmed by its chromatographic overlap with the $\beta 4 GalT7$ assay product. Furthermore, we observed slightly larger products possibly corresponding to double galactosylation by $\beta 4 GalT7$ and $\beta 3 GalT6$ (Fig. 3).

The acetylated compound **19** was thus efficiently taken up by the cells and was *in vivo*-deacetylated to form the active compound, but no increase in chain length of secreted products was observed beyond the non-acetylated variant (ESI Fig. 2†). By analyzing cell lysate from A549 cells treated with compound **5**, we noticed the same product pattern as in the cell medium and could confirm that there was no accumulation of GAGs within the cells (ESI Fig. 3†).

For visualization of uptake and processing of xylosides, the actin skeleton of A549 cells was tagged with green fluorescent protein (GFP). The GFP gene was inserted after the start codon




Fig. 4 Confocal microscopy of GFP-tagged human A549 epithelial cells treated with XylPacBlue (5) and (A) BODIPY TR Ceramide which localizes to the Golgi apparatus or (B) LysoTracker Deep Red which targets lysosomes.

Paper

of the human ACTB gene by CRISPR/Cas9 cleavage in the presence of a donor template, utilizing the natural homologydirected repair pathway. Confocal microscopy experiments after 24 hours of stimulation with 0.1 mM XylPacBlue (5) confirmed uptake and mostly perinuclear localization of the xyloside (Fig. 4). Using Golgi (Fig. 4A) and lysosome (Fig. 4B) trackers, we could confirm the lack of complete co-localization with both Golgi and lysosomes, suggesting that the XylPacBlue derivatives localize to the ER-Golgi intermediate compartment where linker region synthesis takes place.44 Our explanation for these observations is that Golgi entry and further polymerization might be inhibited by the low pK_a (3.7 for PacBlue hydroxyl) of these compounds.

Conclusions

We conclude that compounds 5-9 all have good fluorescent ability and stability§ and are galactosylated by β4GalT7. Furthermore, the compounds permeate A549 cell membranes and are galactosylated in vivo at least once and potentially twice. Interestingly, the biosynthesis is then terminated, and the compounds transported out of the cells. We hypothesize that the compounds are too charged (p K_a 3.7 for PacBlue hydroxyl) to enter the Golgi apparatus to any meaningful extent. The earlier reported compounds 3 and 4, that successfully enter cells and start the GAG synthesis do not have a charge on the fluorophores. We propose that the overall goal, i.e., visualization and tracking of the GAG biosynthesis, may not be possible to reach by fluorescent probes but rather by utilizing compounds that are known to produce GAGs in cells, containing a linker that, after GAG-biosynthesis in the cells, could be modified to attach fluorescent groups.

Experimental section

Synthesis

All moisture- and air-sensitive reactions were carried out under an atmosphere of dry nitrogen using oven-dried glassware. All solvents were dried using MBRAUN SPS-800 Solvent purification system prior to use unless otherwise stated. Purchased reagents were used without further purification. Chromatographic separations were performed on Matrex silica gel (25-70 µm). Thin-layer chromatography was performed on precoated TLC glass plates with silica gel 60 F254 0.25 mm (Merck). Spots were visualized with UV light or by charring with an ethanolic anisaldehyde solution. Biotage Isolute phase separators were used for drying of combined organic layers. Preparative chromatography was performed on Biotage Isolera One flash purification system using Biotage SNAP KP-Sil silica cartridges or Agilent Technologies 1260 Infinity HPLC with Waters Symmetry C18 column, 5 μ m, 19 \times 100 mm was used for purification. Partition coefficient estimation was done using an Agilent Infinity 1260 with an Agilent SB-C18 column, 1.8 μ m, 2.1 \times 50 mm in a gradient of MeCN in H₂O (with 0.1% formic acid in both

solvents). Optical rotations were measured on a Bellingham and Stanley model ADP450 polarimeter and are reported as $\left[\alpha\right]_{D}^{T}$ (c =g/100 mL), D indicate the sodium D line (589 nm) and T indicates the temperature. NMR spectra were recorded at ambient temperatures on a Bruker Avance II at 400 MHz (¹H) and 100 MHz (13C) or a Bruker Ascend at 500 MHz (1H) and 125 MHz (13C) and assigned using 2D methods (COSY, HMQC). Chemical shifts are reported in ppm, with reference to residual solvent peaks ($\delta_{\rm H}$ CHCl₃ = 7.26 ppm, CD₃OH = 3.31 ppm, C₆D₅H = 7.16 ppm) and solvent signals ($\delta_{\rm C}$ CDCl₃ = 77.0 ppm, CD₃OD = 49.0 ppm, $C_6D_6 = 128.06$ ppm). Coupling constant values are given in Hz. Mass spectra were recorded on Waters XEVO G2 (Positive ESI).

Procedure A (general glycosylation procedure)

Glycosyl acceptor (1 eq.) was dissolved in MeCN (dry) under a N_2 -atmosphere along with $BF_3 \cdot OEt_2$ (3 eq.). 1 (3 eq.) dissolved in a minimal amount of MeCN (dry) was added dropwise to the reaction vessel over 2 h. Water (100 mL) was added to the reaction vessel after 2 h and the solution extracted with DCM (3 × 50 mL). The DCM fraction was concentrated in vacuo. Purification by flash chromatography (SiO2, EtOAc: n-heptane $20:80 \rightarrow 60:40$), followed by recrystallisation from 2-propanol gave the product.

Procedure B: (general hydrogenation procedure)

The acetylated carbohydrate intermediate (1 eq.) was dissolved in MeOH (dry). Pd/C (10 mol%, 100 mg g^{-1}) was added, the flask evacuated, flushed with N2 (g), and the atmosphere was changed into H2 (g) (balloon). The reaction was stirred for 2 h after which the solution was filtered through Celite, and the solvent removed in vacuo to yield the product. No further purification was performed.

Procedure C: (general amide coupling procedure)

The free amine intermediate (1 eq.) was dissolved in DCM (dry), and EDC (1.1 eq.), HOBt (1.1 eq., monohydrate), Pacific Blue™ carboxylic acid (1.1 eq.) and TEA (1.1 eq.) were added. The solution was stirred overnight, after which the solvent was removed in vacuo. The crude reaction mixture was purified by preparative HPLC and lyophilized to give the product.

Procedure D (general deacetylation procedure)

The acetylated PacBlue-xyloside (1 eq.) was dissolved in MeOH and K₂CO₃ (0.1 eq.) was added. The solution was stirred for 1 h after which the solution was neutralized using Amberlite IR-120 exchange resin. The resin was filtered off, and the solvent removed in vacuo to yield the product. The crude was purified by preparative HPLC ($H_2O/MeCN 90:10 \rightarrow 0:100$) and lyophilized to give the final compound.

2-((Benzyloxycarbonyl)amino)ethyl 2,3,4-tri-O-acetyl-β-Dxylopyranoside (11). Following procedure A using benzyl (2hydroxyethyl)carbamate (468 mg, 2.40 mmol) and 10 (636 mg, 2.00 mmol) yielded 11 as needle crystals (180 mg, 0.40 mmol, 20%, 100% β-anomer). mp 93.5–94.9 °C; $[\alpha]_D^{25}$ –6.9 (c 1.0,

[§] Compounds left in NMR-tubes dissolved in D2O for three weeks showed no apparent degradation or loss of fluorescence.

CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.39–7.31 (m, 5H, Ar–H), 5.18 (t, J = 8.8 Hz, 1H, H-3), 5.12 (s, 2H, CH₂), 4.96 (td, J = 8.9, 5.2 Hz, 2H, H-4), 4.92 (dd, J = 8.9, 7.0 Hz, 1H, H-2), 4.48 (d, J = 7.0 Hz, 1H, H-1), 4.11 (dd, J = 11.8, 5.2 Hz, 1H, H-5_{eq}), 3.86 (ddd, J = 9.9, 5.8, 4.0 Hz, 1H, -CH₂-N), 3.65 (ddd, J = 10.2, 6.7, 3.8 Hz, 1H, -CH₂-N), 3.48–3.39 (m, 2H, O-CH₂-), 3.36 (dd, J = 11.8, 9.1 Hz, 1H, H-5_{ax}), 2.07 (s, 3H, CH₃), 2.05 (s, 3H, CH₃), 2.03 (s, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 170.01, 169.79, 169.51, 156.33, 136.50, 128.51, 128.12, 128.10, 100.94, 71.46, 70.90, 68.82, 68.69, 66.74, 62.19, 40.81, 20.68, 20.65, 20.60. HRMS calcd for C₂₁H₂₇NO₁₀ + H⁺ (M + H)⁺: 454.1711, found: 454.1713.

2-Aminoethyl 2,3,4-tri-*O*-acetyl-β-D-xylopyranoside (12). 11 (180 mg, 0.40 mmol) was subjected to procedure B to yield 12 as an amorphous solid (128 mg, 0.40 mmol, 100%). $[\alpha]_{\rm D}^{25}$ –2.3 (c 0.4, MeOH). ¹H NMR (400 MHz, MeOD) δ 5.25 (t, J = 9.2 Hz, 1H, H-3), 5.01–4.95 (m, 1H, H-2), 4.96 (dd, J = 9.3, 7.5 Hz, 1H, H-4), 4.71 (d, J = 7.5 Hz, 1H, H-1), 4.12 (dd, J = 11.7, 5.5 Hz, 1H, H-5_{eq}), 4.00 (ddd, J = 10.7, 6.7, 4.0 Hz, 1H, -CH₂-N), 3.88 (ddd, J = 11.5, 5.9, 4.0 Hz, 1H, -CH₂-N), 3.51 (dd, J = 11.7, 9.8 Hz, 1H, H-5_{ax}), 3.18–3.13 (m, 2H, O-CH₂-), 2.06 (s, 3H, CH₃), 2.04 (s, 3H, CH₃), 2.02 (s, 3H, CH₃). ¹³C NMR (101 MHz, MeOD) δ 170.16, 170.12, 170.07, 100.71, 72.03, 71.16, 68.88, 65.03, 62.04, 39.39, 19.22, 19.14, 19.08. HRMS calcd for C₁₃H₂₁NO₈ + Na⁺ (M + Na)⁺: 342.1172, found: 342.1165.

2-(6,8-Difluoro-7-hydroxycoumarin-3-carboxamido)ethyl 2,3,4-tri-*O*-acetyl-β-D-xylopyranoside (13). 12 (40 mg, 0.13 mmol) was subjected to procedure C to yield 13 as a yellow amorphous solid (25 mg, 0.046 mmol, 36%). $[\alpha]_{\rm D}^{25}$ –28.3 (c 0.4, MeCN). ¹H NMR (400 MHz, CDCl₃) δ 8.99 (t, J = 5.4 Hz, 1H, -NH-), 8.77 (d, J = 1.3 Hz, 1H, Ar-H), 7.23 (dd, J = 9.4, 2.0 Hz, 1H, Ar-H), 5.18 (t, J = 8.4 Hz, 1H, H-3), 5.01–4.95 (m, 2H, H-2, H-4), 4.58 (d, J = 6.7 Hz, 1H, H-1), 4.18 (dd, J = 11.9, 5.0 Hz, 1H, H-5_{eq}), 3.98 (ddd, J = 10.2, 5.9, 3.9 Hz, 1H, -CH₂-N), 3.78–3.61 (m, 3H, O-CH₂-,-CH₂-N), 3.42 (dd, J = 11.9, 8.6 Hz, 1H, H-5_{ax}), 2.12 (s, 3H, CH₃), 2.07 (s, 3H, CH₃), 2.03 (s, 3H, CH₃). ¹³C NMR (126 MHz, MeOD) δ 170.12, 170.00, 169.91, 147.92, 109.56, 100.35, 71.81, 70.97, 68.88, 67.33, 63.06, 39.20, 19.23, 19.10, 19.04. HRMS calcd for C₂₃H₂₃NO₁₂F₂ + Na⁺ (M + Na)⁺: 566.1085, found: 566.1086.

2-(6,8-Difluoro-7-hydroxycoumarin-3-carboxamido)ethyl β-Dxylopyranoside (5). 13 (6.8 mg, 0.012 mmol) was subjected to procedure D to yield 5 as a yellow amorphous solid (5.0 mg, 0.012 mmol, 98%). [α]²⁵ 34.1 (c 0.26, MeOH). ¹H NMR (500 MHz, MeOD) δ 9.19 (t, J = 5.5 Hz, 1H, -NH-), 8.75 (d, J = 1.4 Hz, 1H, Ar-H), 7.40 (dd, J = 10.2, 1.9 Hz, 1H, Ar-H), 4.27 (d, J = 7.5 Hz, 1H, H-1), 3.96 (ddd, J = 10.8, 6.7, 4.4 Hz, 1H, O-CH₂-), 3.89 (dd, $J = 11.5, 5.3 \text{ Hz}, 1\text{H}, \text{H-5}_{eq}$, 3.80 (ddd, J = 10.5, 6.0, 4.4 Hz, 1H,O-CH₂-), 3.71-3.61 (m, 2H, -CH₂-N), 3.51 (ddd, J = 10.2, 8.8,5.4 Hz, 1H, H-4), 3.25–3.19 (m, 2H, H-2, H-5_{ax}). ¹³C NMR (126 MHz, MeOD) δ 162.90, 160.44, 150.48 (dd, J = 241.8, 4.3 Hz), 147.68, 144.59 (dd, J = 16.1, 12.8 Hz), 141.32 (d, J = 8.7 Hz), 139.69 (dd, J = 244.5, 6.1 Hz), 113.43, 109.46 (d, J = 21.2 Hz), 107.85 (d, J = 9.8 Hz), 103.85, 76.26, 73.40, 69.66, 67.92, 65.48,39.55. HRMS calcd for $C_{17}H_{17}NO_9F_2 + Na^+(M + Na)^+$: 440.0764, found: 440.0769.

3-((Benzyloxycarbonyl)amino)propyl 2,3,4-tri-*O*-acetyl-β-D-xylopyranoside (14). Following procedure A using benzyl (4-

hydroxypropyl)carbamate (502 mg, 2.4 mmol) and **10** (636 mg, 2.0 mmol) to yield **14** as needle crystals (229 mg, 0.49 mmol 20%, 100% β-anomer). mp 96.1–97.0 °C; $[\alpha]_D^{25}$ –19.2 (c 0.6, MeOH). ¹H NMR (400 MHz, CDCl₃) δ 7.38–7.28 (m, 5H, Ar), 5.16 (t, J=8.6 Hz, 1H, H-3), 5.09 (s, 2H, –CH₂–Ar), 5.00 (broad, 1H, –NH–), 4.96–4.87 (m, 2H, H-2, H-4) 4.46 (d, J=6.8 Hz, 1H, H-1), 4.10 (dd, J=11.8, 5.1 Hz, 1H, H-5_{eq}), 3.88 (dt, J=9.9, 5.9 Hz, 1H, O–CH₂–), 3.54 (dt, J=9.9, 5.9 Hz, 1H, O–CH₂–), 3.54 (dt, J=9.9, 5.9 Hz, 1H, O–CH₂–), 3.35 (dd, J=11.8, 8.8 Hz, 1H, H-5_{ax}), 3.31–3.20 (m, 2H –CH₂–N), 2.05 (s, 3H, Ac), 2.03 (s, 3H, Ac), 2.02 (s, 3H, Ac), 1.83–1.73 (m, 2H –CH₂–). ¹³C NMR (101 MHz, CDCl₃) δ 170.08, 169.85, 169.54, 156.41, 136.64, 128.52, 128.11, 128.08, 100.59, 71.35, 70.76, 68.82, 67.33, 66.59, 62.05, 38.46, 29.50, 20.75, 20.70, 20.69. HRMS calcd for $C_{22}H_{29}NO_{10} + H^+$ (M + H)[†]: 468.1870, found: 468.1863.

3-Aminopropyl 2,3,4-tri-*O*-acetyl-β-D-xylopyranoside (15). 14 (229 mg, 0.49 mmol) was subjected to procedure B to yield 15 as a clear oil (156 mg, 0.47 mmol, 96%). $[\alpha]_D^{25}$ –5.7 (*c* 0.5, MeOH). ¹H NMR (400 MHz, MeOD) δ 5.25 (t, J = 9.2 Hz, 1H, H-3), 4.98–4.93 (m, 2H, H-2, H-4), 4.62 (d, J = 7.4 Hz, 1H, H-1), 4.10 (dd, J = 11.7, 5.5 Hz, 1H, H-5_{eq}), 3.96 (ddd, J = 10.1, 6.5, 5.2 Hz, 1H, O-CH₂–), 3.74–3.67 (m, 1H, O-CH₂–), 3.48 (dd, J = 11.7, 9.8 Hz, 1H, H-5_{ax}), 3.04 (t, J = 7.1 Hz, 2H, -CH₂–N), 2.07 (s, 3H, Ac), 2.04 (s, 3H, Ac), 2.03 (s, 3H, Ac), 1.98–1.90 (m, 2H, -CH₂–). ¹³C NMR (101 MHz, MeOD) δ 170.15, 170.14, 168.46, 100.74, 71.80, 71.38, 69.01, 66.61, 61.93, 37.47, 27.13, 19.23, 19.15, 19.11. HRMS calcd for C₁₄H₂₃NO₈ + H⁺ (M + H)⁺: 334.1503, found: 334.1502.

3-(6,8-Difluoro-7-hydroxycoumarin-3-carboxamido)propyl **2,3,4-tri-***O*-acetyl-β-D-xylopyranoside (16). 15 (40 mg, 0.12 mmol) was subjected to procedure C to yield 16 as a yellow amorphous solid (28 mg, 0.048 mmol, 40%). $[\alpha]_{\rm D}^{25}$ -67.7 (c 0.53, MeCN). ¹H NMR (400 MHz, MeOD) δ 9.01 (t, J = 5.7 Hz, 1H, -NH-), 8.74 (d, J= 1.4 Hz, 1H, Ar, 7.44 (dd, J = 10.2, 2.1 Hz, 1H, Ar), 5.20 (t, J = 1.4 Hz, 1H, 1H, 1H)9.0 Hz, 1H, H-3), 4.96–4.91 (m, 1H, H-4)*, 4.91 (t, J = 2.7 Hz, 1H, H--2, 4.61 (d, J = 7.3 Hz, 1H, H-1), 4.09 (dd, J = 11.7, 5.4 Hz, 1H, $H-5_{eq}$), 3.91 (dt, J = 10.0, 5.9 Hz, 1H, O-CH₂-), 3.65 (dt, J = 10.0, 5.9 Hz, 1H, O-CH₂-), 3.53-3.47 (m, 2H, -CH₂-N), 3.46 (dd, J =11.7, 9.5 Hz, 1H, H-5_{ax}), 2.03 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.87 (p, J = 6.2 Hz, 2H, -CH₂-). ¹³C NMR (101 MHz, MeOD) δ 170.25, 170.12, 169.87, 162.45, 160.31, 147.42, 115.33, 109.87, 109.84, 109.81, 109.63, 109.35, 100.76, 71.99, 71.22, 69.06, 66.92, 61.77, 36.62, 28.83, 19.24, 19.19, 19.14. HRMS calcd for $C_{24}H_{25}NO_{12}F_2 + Na^+ (M + Na)^+$: 580.1229, found: 580.1243. *Overlapping with solvent peak, assigned with COSY experiment.

3-(6,8-Difluoro-7-hydroxycoumarin-3-carboxamido)propyl β-D-xylopyranoside (6). 16 (6.1 mg, 0.011 mmol) was subjected to procedure D to yield 6 as a yellow amorphous solid (4.8 mg, 0.011 mmol, 96%) $[\alpha]_D^{25}$ –12.0 (c 0.81, MeOH). ¹H NMR (400 MHz, MeOD) δ 9.12 (t, J = 5.6 Hz, 1H, –NH–), 8.75 (d, J = 1.4 Hz, 1H, Ar), 7.42 (dd, J = 10.2, 2.0 Hz, 1H, Ar), 4.23 (d, J = 7.4 Hz, 1H, H-1), 3.94 (ddd, J = 10.0, 6.8, 5.4 Hz, 1H, O–CH₂–), 3.89 (dd, J = 11.4, 5.4 Hz, 1H, H-5_{eq}), 3.73–3.66 (m, 1H, O–CH₂–), 3.57 (dt, J = 10.8, 5.5 Hz, 2H, –CH₂–N), 3.51 (ddd, J = 10.3, 7.8, 4.5 Hz, 1H, H-5_{ax}), 3.36–3.19 (m, 3H, H-2, H-3, H-4)*, 1.97–1.88 (m, 2H, –CH₂–). ¹³C NMR (101 MHz, MeOD) δ 162.59, 160.45, 147.59, 114.37, 109.75, 108.63, 103.85, 76.48, 73.47, 69.82, 67.16, 65.62, 36.88, 29.00. HRMS calcd for $C_{18}H_{19}NO_9F_2$ + H⁺ (M + H)⁺: 432.1106,

found: 432.1097. *Overlapping with solvent peak, assigned with COSY experiment.

4-((Benzyloxycarbonyl)amino)butyl 2,3,4-tri-O-acetyl-β-Dxylopyranoside (17). Following procedure A using benzyl (4hydroxybutyl)carbamate (536 mg, 2.4 mmol) and 10 (636 mg, 2.0 mmol) to yield 17 as needle crystals (134 mg, 0.28 mmol, 14%, 100% β-anomer). mp 96.2–98.5 °C; $[\alpha]_D^{25}$ –16.4 (*c* 0.7, MeOH). ¹H NMR (400 MHz, CDCl₃) δ 7.39–7.31 (m, 5H, Ar), 5.18 (t, I =8.6 Hz, 1H, H-3), 5.11 (s, 2H, $-CH_2$ -), 4.96 (td, J = 8.8, 5.1 Hz, 1H, H-4), 4.92 (dd, J = 8.7, 6.9 Hz, 1H, H-2), 4.85 (broad, s, 1H, -NH-), 4.47 (d, J = 6.8 Hz, 1H, H-1), 4.12 (dd, J = 11.8, 5.1 Hz, 1H, H- 5_{eq}), 3.85 (dt, J = 9.9, 5.9 Hz, 1H, O-CH₂), 3.51 (dt, J = 9.6, 5.7 Hz, 1H, O-CH₂), 3.36 (dd, J = 11.8, 8.9 Hz, 1H, H-5_{ax}), 3.23 $(q, J = 6.3 \text{ Hz}, 2H, -CH_2-N), 2.07 (s, 3H, Ac), 2.06 (s, 3H, Ac), 2.05$ (s, 3H, Ac), 1.65-1.56 (m, 4H, -CH₂-CH₂-). ¹³C NMR (101 MHz, $CDCl_3$) δ 170.06, 169.81, 169.43, 156.40, 136.66, 128.51, 128.07, 100.70, 71.51, 70.91, 69.06, 68.92, 66.60, 62.07, 40.63, 26.61, 26.57, 20.71, 20.68, 20.67. HRMS calcd for $C_{23}H_{31}NO_{10} + H^+(M +$ H)+: 482.2024, found: 482.2026.

3-Aminobutyl 2,3,4-tri-*O*-acetyl-β-D-xylopyranoside (18). 17 (134 mg, 0.28 mmol) was subjected to procedure B to yield 18 as a clear sticky solid (91 mg, 0.027 mmol, 94%) $[\alpha]_D^{25}$ –4.2 (c 0.7, MeOH). ¹H NMR (400 MHz, MeOD) δ 5.23 (t, J = 9.2 Hz, 1H, H-3), 4.96–4.92 (m, 1H, H-4)*, 4.86 (dd, J = 9.3, 7.4 Hz, 1H, H-2), 4.60 (d, J = 7.4 Hz, 1H, H-1), 4.08 (dd, J = 11.7, 5.4 Hz, 1H, H-5_{eq}), 3.88 (dt, J = 9.8, 5.7 Hz, 1H, O–CH₂–), 3.61 (dt, J = 9.8, 5.7 Hz, 1H O–CH₂–), 3.47 (dd, J = 11.7, 9.8 Hz, 1H, H-5_{ax}), 2.95 (t, J = 6.8 Hz, 2H, CH₂–N), 2.06 (s, 3H, Ac), 2.03 (s, 3H, Ac), 2.02 (s, 3H, Ac), 1.78–1.65 (m, 4H, –CH₂–CH₂–). ¹³C NMR (101 MHz, MeOD) δ 170.16, 170.13, 169.96, 100.77, 71.97, 71.39, 69.06, 68.50, 61.87, 39.16, 26.10, 24.32, 19.22, 19.15, 19.10. HRMS calcd for C₁₅H₂₅NO₈ + H⁺ (M + H)⁺: 348.1659, found: 348.1658. *Overlapping with solvent peak, assigned with COSY experiment.

4-(6,8-Difluoro-7-hydroxycoumarin-3-carboxamido)butyl 2,3,4-tri-O-acetyl-β-p-xylopyranoside (19). 18 (41.4 mg, 0.121 mmol) was subjected to procedure C to yield 19 as a yellow amorphous solid (41.5 mg, 0.0698 mmol, 58%) $\left[\alpha\right]_{D}^{2.5}$ 35.2 (c 0.39, MeCN). ¹H NMR (400 MHz, MeOD) δ 8.98 (t, J = 5.6 Hz, 1H, -NH-), 8.77 (d, J=1.5 Hz, 1H, Ar), 7.48 (dd, J=10.2, 2.1 Hz, 1H, Ar), 5.20 (t, J = 9.0 Hz, 1H, H-3), 4.93 (dd, J = 9.5, 5.4 Hz, 1H, H-4)*, 4.86 (dd, J = 9.1, 7.3 Hz, 1H, H-2)*, 4.60 (d, J = 7.3 Hz, 1H, H-1), 4.07 (dd, J = 11.7, 5.4 Hz, 1H, $H-5_{eq}$), 3.92-3.85 (m, 1H, O-CH₂-), 3.62-3.55 (m, 1H, O-CH₂-), 3.46 (m, 2H, CH₂-N), 3.46 (dd, J = 11.7, 9.5 Hz, 1H, H-5_{ax}), 2.04 (s, 3H, Ac), 2.03 (s, 3H, Ac),2.01 (s, 3H, Ac), 1.72-1.66 (m, 4H, -CH₂-CH₂-). ¹³C NMR (101 MHz, MeOD) δ 170.22, 170.11, 169.85, 162.34, 147.44, 115.63, 109.93, 100.66, 71.94, 71.23, 69.05, 68.77, 61.70, 38.94, 26.50, 25.71, 19.25, 19.18, 19.13. HRMS calcd for $C_{25}H_{27}NO_{12}F_2 + H^+$ (M + H)+: 594.1396, found: 594.1399. *Partially overlapping with solvent peak, assigned with COSY experiment.

4-(6,8-Difluoro-7-hydroxycoumarin-3-carboxamido)butyl β-D-**xylopyranoside** (7). **19** (6.5 mg, 0.011 mmol) was subjected to procedure D to yield 7 as a yellow amorphous solid (4.8 mg, 0.011 mmol, 96%). $[\alpha]_{\rm D}^{25}$ +63.8 (*c* 0.70, MeOH). ¹H NMR (500 MHz, MeOD) δ 9.00 (t, J = 5.7 Hz, 1H, -NH-), 8.76 (d, J = 1.5 Hz, 1H, Ar), 7.46 (dd, J = 10.1, 2.0 Hz, 1H, Ar), 4.22 (d, J = 7.6 Hz, 1H,

H-1), 3.89 (dt, J = 9.8, 6.0 Hz, 1H, O–CH₂–), 3.86 (dd, J = 11.5, 5.4 Hz, 1H, H-5_{eq}), 3.61 (dt, J = 9.8, 5.9 Hz, 1H, O–CH₂–), 3.52–3.45 (m, 3H, H-4, –CH₂–N), 3.32–3.29 (m, 1H, H-3), 3.24–3.16 (m, 2H, H-2, H-5_{ax}), 1.80–1.69 (m, 4H, –CH₂–CH₂–). ¹³C NMR (126 MHz, MeOD) δ 162.38, 160.29, 147.41, 109.57, 103.68, 76.40, 73.47, 69.75, 68.84, 65.47, 38.97, 26.55, 25.65. HRMS calcd for C₁₉H₂₁NO₉F₂ + Na⁺ (M + Na)⁺: 468.1078, found: 468.1082.

((2R)-(Benzyloxycarbonyl)amino)propyl 2,3,4-tri-O-acetyl-β-D-xylopyranoside (20). Following procedure A using benzyl (R)-(1-hydroxypropan-2-yl)carbamate (536 mg, 2.4 mmol) and 10 (636 mg, 2.0 mmol) to yield 20 as needle crystals (236 mg, 0.50 mmol, 21%, 100% β-anomer). mp 86.3–89.3 °C; $[\alpha]_D^{25}$ –18.6 (c 0.8, MeOH). ¹H NMR (400 MHz, CDCl₃) δ 7.39–7.32 (m, 5H, Ar), 5.18 (t, J = 8.5 Hz, 1H, H-3), 5.11 (s, 2H, -CH₂-), 4.96 (dd, J =8.6, 5.0 Hz, 1H, H-4), 4.93 (dd, J = 8.7, 6.7 Hz, 1H, H-2), 4.48 (d, J $= 6.7 \text{ Hz}, 1\text{H}, \text{H-1}, 4.12 (dd, J = 11.8, 5.1 \text{ Hz}, 1\text{H}, \text{H-5}_{eq}), 3.98-$ 3.91 (m, 1H, O-CH₂-), 3.77 (dd, J = 9.6, 3.9 Hz, 1H, CH), 3.57- $3.52 \text{ (m, 1H, O-CH}_2$ -), $3.37 \text{ (dd, } J = 11.6, 9.0 \text{ Hz, 1H, H-5}_{ax}\text{), } 2.07$ (s, 3H, Ac), 2.05 (s, 3H, Ac), 2.01 (s, 3H, Ac), 1.21 (d, J = 6.8 Hz)3H, CH₃). 13 C NMR (101 MHz, CDCl₃) δ 170.01, 169.85, 169.59, 155.65, 136.47, 128.53, 128.15, 100.78, 72.20, 71.18, 70.68, $68.75, 66.65, 62.00, 46.49, 20.75, 20.71, 20.61, 17.80, C_{22}H_{29}NO_{10}$ + H⁺ (M + H)⁺: 468.1864, found: 468.1870.

(2*R*)-2-Aminopropyl 2,3,4-tri-*O*-acetyl-β-D-xylopyranoside (21). 20 (236 mg, 0.505 mmol) was subjected to procedure B to yield 21 as a clear sticky solid (103 mg, 0.310 mmol, 62%). [α]_D²⁵ -6.3 (c 0.9, MeOH). ¹H NMR (400 MHz, MeOD) δ 8.45 (s, 1H, NH₂, exchangeable), 5.25 (t, J = 9.1 Hz, 1H, H-3), 5.01-4.94 (m, 2H, H-2, H-4)*, 4.71 (d, J = 7.4 Hz, 1H, H-1), 4.12 (dd, J = 11.7, 5.4 Hz, 1H, H-5_{eq}), 3.79 (d, J = 5.9 Hz, 2H, O-CH₂-), 3.55-3.44 (m, 2H, H-5_{ax}, CH), 2.06 (s, 3H, Ac), 2.04 (s, 3H, Ac), 2.03 (s, 3H, Ac), 1.29 (d, J = 6.8 Hz, 3H, CH₃). ¹³C NMR (101 MHz, MeOD) δ 170.15, 170.13, 170.07, 167.43, 100.21, 71.91, 71.05, 69.43, 68.84, 61.95, 19.25, 19.17, 19.12, 13.77. C₁₄H₂₃NO₈ + Na⁺ (M + Na)⁺: 334.1500, found: 334.1502. *Partially overlapping with solvent peak, assigned by COSY experiment.

((2R)-2-(6,8-Difluoro-7-hydroxycoumarin-3-carboxamido)) propyl 2,3,4-tri-O-acetyl-β-D-xylopyranoside (22). 21 (40 mg, 0.12 mmol) was subjected to procedure C to yield 22 as a bright yellow solid (38 mg, 0.066 mmol, 55%). $[\alpha]_D^{25}$ -58.4 (c 0.40, MeCN). ¹H NMR (400 MHz, MeOD) δ 9.02 (d, J = 7.9 Hz, 1H, -NH-), 8.78 (d, J=1.4 Hz, 1H, Ar), 7.47 (dd, J=10.2, 2.0 Hz, 1H, Ar), 5.12 (t, J = 8.8 Hz, 1H, H-3), 5.00–4.92 (m, 2H, H-2, H-4)*, 4.66 (d, J = 7.1 Hz, 1H, H-1), 4.35-4.26 (m, 1H, CH), 4.11 (dd, J = 4.66 (d, J = 7.1 Hz, 1H, H-1), 4.35-4.26 (m, 1H, CH), 4.11 (dd, J = 4.66 (d, J = 7.1 Hz, 1H, H-1), 4.35-4.26 (m, 1H, CH), 4.11 (dd, J = 4.66 (d, J = 7.1 Hz, 1H, H-1), 4.35-4.26 (m, 1H, CH), 4.11 (dd, J = 4.66 (d, J = 7.1 Hz, 1H, H-1), 4.35-4.26 (m, 1H, CH), 4.11 (dd, J = 4.66 (d, J = 7.1 Hz, 1H, H-1), 4.35-4.26 (m, 1H, CH), 4.11 (dd, J = 4.66 (d, J11.7, 5.3 Hz, 1H, H-5_{eq}), 3.91 (dd, J = 9.9, 4.4 Hz, 1H, O-CH₂-), 3.63 (dd, J = 9.9, 4.2 Hz, 1H, O-CH₂-), 3.49 (dd, J = 11.8, 9.3 Hz,1H, H-5_{ax}), 2.08 (s, 3H, Ac), 2.03 (s, 3H, Ac), 2.02 (s, 3H, Ac), 1.28 (d, J = 6.8 Hz, 3H, CH₃). ¹³C NMR (101 MHz, MeOD) δ 170.21, 170.14, 170.06, 161.75, 160.32, 147.71, 109.71, 100.40, 71.78, 71.19, 70.99, 68.97, 61.64, 45.33, 19.37, 19.18, 19.13, 16.10. HRMS calcd for $C_{24}H_{25}NO_{12}F_2 + Na^+ (M + Na)^+$: 580.1241, found: 580.1243. *Overlapping with solvent peak, assigned by COSY experiment.

((2*R*)-2-(6,8-Difluoro-7-hydroxycoumarin-3-carboxamido)) propyl β-D-xylopyranoside (8). 22 (10.1 mg, 0.018 mmol) was subjected to procedure D to yield 8 (5.7 mg, 0.013 mmol, 73%) as a bright yellow solid. $[\alpha]_D^{25}$ –114 (*c* 0.1, MeOH). ¹H NMR (400

MHz, MeOD) δ 8.98 (d, J = 8.1 Hz, 1H, -NH-), 8.76 (d, J = 1.4 Hz, 1H, Ar), 7.46 (dd, J = 10.2, 2.0 Hz, 1H, Ar), 4.39-4.29 (m, 1H, -CH-), 4.26 (d, J = 7.5 Hz, 1H, H-1), 3.91-3.85 (m, 2H, O-CH₂-, H-5_{eq}), 3.67 (dd, J = 10.2, 4.7 Hz, 1H, O-CH₂-), 3.53-3.45 (m, 1H, H-5_{ax}), 3.33 (m, 1H, H-3)* 3.27-3.16 (m, 2H, H-2,H-4), 1.31 (d, J = 6.8 Hz, 3H, -CH₃). 13 C NMR (101 MHz, MeOD) δ 162.06, 160.32, 147.55, 115.24, 109.88, 103.95, 76.31, 73.45, 72.13, 69.75, 65.55, 45.67, 16.11. HRMS calcd for C₁₈H₁₉NO₉F₂ + Na⁺ (M+Na)⁺: 454.0926, found: 454.0921. *Overlapping with solvent peak, assigned by COSY experiment.

2-((tert-Butyloxycarbonyl)amino)ethyl 2,3,4-tri-O-acetyl-1,5dithio-β-D-xylopyranoside (24). ZnCl₂ (55.1 mg, 0.67 mmol), ZnO (90.0 mg, 0.67) and 2-(BOC-amino)ethanethiol (361 mg, 2.0 mmol) were dissolved in a 1:1 mixture of MeCN and toluene (20 mL), together with molecular sieves (3 Å). The mixture was heated to 50 °C for 20 minutes, after which 23 (180 mg, 0.51 mmol) was added. The reaction was kept at 50 °C for 2 h. The mixture was then diluted with DCM (40 mL), washed with NaHCO₃ (2 \times 30 mL, sat. aq.) and brine (2 \times 30 mL). The organic phase was dried and concentrated in vacuo. Purification by flash chromatography (39:59:2 EtOAc/n-heptanes/TEA) yielded 24 (92 mg, 40%, 2 : 1 β : α) as an amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 5.37 (t, J = 9.8 Hz, 1H, H-4), 5.14–5.07 (m, 1H, H-2), 5.06-5.03 (m, 1H, H-3), 3.77 (d, J = 10.3 Hz, 1H, H-4)1), 3.37-3.29 (m, 2H, $-CH_2-N$), 2.86 (t, J = 6.5 Hz, 2H, $S-CH_2-$), 2.76–2.71 (m, 2H, H-5), 2.02 (m, 9H, Ac), 1.44 (s, 9H, t-Bu). ¹³C NMR (101 MHz, CDCl₃) δ 169.73, 169.71, 169.64, 73.93, 73.00, 72.37, 70.22, 48.49, 40.07, 31.45, 31.37, 28.40, 20.62, 20.60, 20.55. HRMS calcd for $C_{18}H_{29}NO_8S_2 + Na^+ (M + Na)^+: 474.1231$, found: 474.1232.

2-((tert-Butyloxycarbonyl)amino)ethyl 2,3,4-tri-O-acetyl-1,5-dithio-α-d-xylopyranoside. 1 H NMR (400 MHz, CDCl $_3$) δ 5.37 (t, J = 9.8 Hz, 1H, H-3), 5.22 (dd, J = 10.2, 4.5 Hz, 1H, H-2), 5.02–4.98 (m, 1H, H-4), 4.45 (dd, J = 4.5, 1.5 Hz, 1H, H-1), 3.37–3.28 (m, 2H, –CH $_2$ –N)*, 3.12 (dd, J = 13.3, 11.3 Hz, 1H, H-5 $_{\rm eq}$), 2.75–2.71 (m, 2H, S–CH $_2$ –), 2.68–2.62 (m, 1H, H-5 $_{\rm ax}$), 2.07 (s, 3H, Ac), 2.03 (s, 3H, Ac), 2.02 (s, 3H, Ac), 1.44 (s, 9H, t-Bu)*. 13 C NMR (101 MHz, CDCl $_3$) δ 169.89, 74.64, 73.39, 72.99, 70.22, 49.76, 40.06, 25.67′, 25.09′, 28.37, 20.83, 20.79. HRMS calcd for C $_{18}$ H $_{29}$ NO $_{8}$ S $_2$ + Na $^+$ (M + Na) $^+$: 474.1231, found: 474.1232. *Overlapping with corresponding peak for β-anomer. Assigned with HSQC experiment.

2-((*tert*-Butyloxycarbonyl)amino)ethyl 1,5-dithio-β-D-xylopyranoside (25). 24 (88.0 mg, 0.20 mmol) was dissolved in MeOH (10 mL). LiOH (18.7 mg, 0.78 mmol) was added, and the mixture was stirred for 40 minutes. The mixture was neutralized with Amberlite IR120 (H⁺) which was then filtered of. The mixture was concentrated *in vacuo* and purified by flash chromatography (9:1 DCM: EtOH with 2% TEA) to yield 25 (62.5 mg, 98%, 2:1 β: α) as an amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 3.82 (ddd, J = 10.2, 9.4, 5.1 Hz, 1H, H-4), 3.65 (d, J = 10.2 Hz, 1H, H-1), 3.52–3.50 (m, 1H, H-2), 3.38 (t, J = 6.1 Hz, 2H, S–CH₂–), 3.28 (t, J = 8.9 Hz, 1H, H-3), 3.12 (qd, J = 7.3, 4.9 Hz, 2H, –CH₂–N), 2.73–2.67 (m, 2H, H-5), 1.45 (s, 9H, *t*-Bu). ¹³C NMR (101 MHz, CDCl₃) δ 156.65, 79.17, 75.50, 73.46, 72.57, 50.79, 45.92, 33.51, 28.44, 28.41. HRMS calcd for C₁₂H₂₃NO₅S₂ + H⁺ (M + H)⁺: 326.1096, found: 326.1090.

2-((*tert*-Butyloxycarbonyl)amino)ethyl 1,5-dithio-α-p-xylopyranoside. 1 H NMR (400 MHz, CDCl $_3$) δ 4.16 (d, J = 3.3 Hz, 1H, H-1), 4.04 (dd, J = 9.4, 4.3 Hz, 1H, H-2), 3.78–3.76 (m, 1H, H-4), 3.55–3.49 (m, 1H, H-3), 3.36–3.32 (m, 2H, S–CH $_2$ –)*, 3.07–2.96 (m, 1H, H-5 $_{eq}$), 2.89–2.82 (m, 2H, –CH $_2$ –N), 2.63–2.58 (m, 1H, H-5 $_{ax}$), 1.44 (s, 9H, t-Bu)*. 13 C NMR (101 MHz, CDCl $_3$) δ 75.05, 73.46, 53.32, 34.46, 31.99, 28.44. HRMS calcd for C $_{12}$ H $_{23}$ NO $_5$ S $_2$ + H $^+$ (M + H) $^+$: 326.1096, found: 326.1090. *Overlapping with corresponding peak for β-anomer.

2-Aminoethyl 1,5-dithio-β-D-xylopyranoside (26).(62.5 mg, 0.191 mmol) was dissolved in EtOH (5 mL). HCl (1 M, 5 mL) was added, and the mixture was stirred for 1 h, after which the solvent was removed in vacuo. The residue was purified by preparatory HPLC ($H_2O: MeCN 90: 10 \rightarrow 0: 100$) and lyophilized to yield β-26 (22.5 mg, 0.10 mmol, 52%) as an amorphous solid. $[\alpha]_{D}^{25}$ +51.0 (c 0.3, D₂O). ¹H NMR (400 MHz, D_2O) δ 3.86 (d, J = 10.3 Hz, 1H, H-1), 3.74 (td, J = 9.6, 5.8 Hz, 1H, H-4), 3.47 (t, J = 9.8 Hz, 1H, H-2), 3.28 (t, J = 6.9 Hz, 2H, H-2), 3.24 (t, J = 9.5 Hz, 2H, S-CH₂-), 3.09 (dt, J = 14.3, 7.0, 1H, H- 5_{eq}), 2.99 (dt, J = 14.3, 7.0 Hz, 1H, H- 5_{ax}), 2.71 (dd, J = 7.8, 3.5 Hz, 2H, $-CH_2-N$). ¹³C NMR (101 MHz, D_2O) δ 78.12, 75.50, 72.55, 49.36, 38.95, 33.00, 28.10. HRMS calcd for C₇H₁₅NO₃S₂ + $H^{+}(M + H)^{+}$: 226.0572, found: 226.0565.

2-(6,8-Difluoro-7-hydroxycoumarin-3-carboxamido)ethyl 1,5dithio-β-D-xylopyranoside (9). 26 (5.1 mg, 0.023 mmol) was dissolved in DMF (3 mL) along with Pacific Blue™ succinimidyl ester (15.8 mg, 0.047 mmol). DIPEA (4.0 μL, 0.093 mmol) was added and the reaction was stirred for 4 h at r.t. The solvent was removed in vacuo. The residue was purified by preparatory HPLC (H_2O : MeCN 90: 10 \rightarrow 0: 100) and lyophilized to yield 9 as a yellow amorphous solid (4.5 mg, 0.010 mmol, 46%). $\left[\alpha\right]_{D}^{25}$ -146 (c 0.72, MeOH). ¹H NMR (500 MHz, MeOD) δ 9.23 (t, J = 5.8 Hz, 1H, -NH-), 8.71 (d, J =1.5 Hz, 1H, Ar), 7.31 (dd, J = 10.4, 1.8 Hz, 1H, Ar), 3.79 (d, J =10.2 Hz, 1H, H-1), 3.69 (td, J = 6.8, 3.2 Hz, 2H, S-CH₂-), 3.64 (ddd, J = 10.8, 9.1, 4.5 Hz, 1H, H-4), 3.38 (dd, J = 10.2, 8.7 Hz,1H, H-2), 3.15 (t, J = 8.9 Hz, 1H, H-3), 3.02–2.91 (m, 2H, -CH₂-N), 2.68 (dd, J = 13.4, 10.9 Hz, 1H, H-5_{eq}), 2.58 (dd, J = 13.4, 4.5 Hz, 1H, H-5_{ax}). 13 C NMR (126 MHz, MeOD) δ 163.42, 161.10, 151.75 (dd, J = 241.2, 6.5 Hz), 147.98, 141.84 (d, J = 8.9Hz), 140.41 (dd, J = 241.6, 7.9 Hz), 110.79, 109.12 (dd, J = 21.4, 2.0 Hz), 105.89 (d, J = 10.8 Hz), 78.95, 76.23, 72.97, 50.55, 39.42, 33.41, 30.46. HRMS calculated for $C_{17}H_{17}NO_7S_2F_2 + H^+$ $(M + H)^+$, 450.0493; found: 450.0486.

β4GalT7 assay

The $\beta 4GalT7$ enzymatic assay was performed as previously described. Briefly, $\beta 4GalT7$ (50 ng) was mixed in 96-well polypropylene plates with UDP-Gal (1 mM final concentration) and various concentrations of xylosides in a final volume of 50 μL MES buffer (20 mM, pH 6.2) supplemented with MnCl₂ (10 mM). Incubation was performed at 37 °C for 30 min and the reaction was stopped by cooling at 4 °C and addition of HPLC eluent (70% NH₄OAc (60 mM, pH 5.6) – 30% CH₃CN (v/v)) before HPLC analysis.

Paper RSC Advances

GFP tagging of the ACTB gene in human A549 epithelial cells

To N-terminally tag the human actin protein (cytoplasmic 1, encoded by ACTB) of A549 cells with GFP, we used the Invitrogen TrueTag DNA donor kit (Thermo Fisher Scientific) which utilizes the natural homology directed repair pathway. CRISPR/Cas9 cleavage was performed in the presence of a donor template containing puromycin resistance and Emerald GFP genes (N-Puro-EmGFP), with ACTB-matching homology arms on each side of the inserted genes. The following primers, with 2× phosphorothioate modifications at the 5' ends, were used to PCR amplify the donor template (non-bolded bases homologous to the ACTB gene and bolded homologous to N-Puro-EmGFP):

5'-TTGTCGACGACGAGCGCGGCGAT ATCATCATCACCGCTTCCACTACCTGAACC

The purified PCR product was co-transfected with the True-Cut Cas9 v2 protein and a TrueGuide synthetic guide RNA complexed to BSA (Thermo Fisher Scientific) at a final concentration of 5 μ M. Compound 5 was used at a final concentration of 100 μ M. Cells were left together with the substances at 37 °C for 100 min, after which the cell layer was washed twice with Dulbecco's Phosphate Buffered Saline (Sigma-Aldrich) and then covered with OptiPRO SFM medium before imaging.

Author contributions

Roberto Mastio: investigation, formal analysis, visualization, writing – original draft, writing – review & editing. Daniel Willén: conceptualization, supervision, investigation, visualization, writing – original draft, writing – review & editing. Zackarias Söderlund: investigation, methodology, writing – review & editing. Gunilla Westergren-Thorsson: supervision, writing – review & editing. Emil Tykesson: investigation, supervision, visualization, writing – original draft, writing – review & editing. Ulf Ellervik: conceptualization, funding acquisition,

5'-AGCGCGCCGGCTATTCTCGCAGCTCACCATG GGAGGTAAGCCCTTGCATTCG

(GCGGCGAUAUCAUCAUCA, TGG PAM site) into A549 cells (ATCC CCL-185) using Lipofectamine CRISPRMAX Cas9 transfection reagent.

Modified cells were selected by FACS and verified using the following junction primers:

ACTB-F primer: 5'-GACGCCTCCGACCAGTGTTTGCC. N-Puro-EmGFP-R: 5'-GGGTAATCGGCGAAGGCAGCGG.

Xyloside stimulation of A549 cells

Actin-EmGFP-modified A549 cells were cultured to approx. 70% confluence in DMEM/F-12/GlutaMAX (Thermo Fisher Scientific) supplemented with 10% FBS (Thermo Fisher Scientific), 100 units per mL penicillin and 100 μg mL $^{-1}$ streptomycin (Sigma-Aldrich). For xyloside treatment, the growth medium was aspirated and xylosides (100 μM from 50 mM stock solution in DMSO) in OptiPRO SFM medium (Thermo Fisher Scientific) was added to the cells. After 24 h of treatment, medium samples were either analyzed directly by fluorescence detection size-exclusion chromatography (FSEC) on an AdvanceBio SEC column (Agilent) or purified on an anion exchange DE52 diethylaminoethyl cellulose resin (Sigma-Aldrich). Purified samples were subsequently analyzed by FSEC or reversed-phase chromatography on an ACE C8, 3 μm 4.6 \times 100 mm (ACE).

Confocal microscopy of A549 cells

Localization experiments were performed on a Nikon Confocal A1RHD microscope with cells seeded on Lab-Tek 8-well (0.8 cm²) borosilicate (0.17 mm) slides (Thermo Fisher Scientific). For staining of lysosomes, LysoTracker Deep Red (Thermo Fisher Scientific) was used at a final concentration of 50 nM. Staining of the Golgi apparatus was performed using BODIPY TR Ceramide

supervision, visualization, writing – original draft, writing – review & editing.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The work was supported by grants from the Crafoord Foundation, the Swedish Heart Lung Foundation, Lund University, and the Royal Physiographic Society in Lund. Parts of Fig. 1 are produced by www.biorender.com.

Notes and references

- 1 V. Pomin and B. Mulloy, Pharmaceuticals, 2018, 11, 27.
- 2 X. V. Victor, T. K. N. Nguyen, M. Ethirajan, V. M. Tran, K. V. Nguyen and B. Kuberan, *J. Biol. Chem.*, 2009, 284, 25842–25853.
- 3 F. N. Lugemwa and J. D. Esko, J. Biol. Chem., 1991, 266, 6674-6677.
- 4 T. A. Fritz, F. N. Lugemwa, A. K. Sarkar and J. D. Esko, *J. Biol. Chem.*, 1994, 269, 300–307.
- 5 S. O. Kolset, K. Sakurai, I. Ivhed, A. Overvatn and S. Suzuki, *Biochem. J.*, 1990, **265**, 637–645.
- 6 R. Johnsson, K. Mani and U. Ellervik, *Bioorganic Med. Chem.*, 2007, **15**, 2868–2877.
- 7 M. Jacobsson, C. Winander, K. Mani and U. Ellervik, *Bioorganic Med. Chem. Lett.*, 2008, **18**, 2451–2454.
- 8 M. Jacobsson, K. Mani and U. Ellervik, *Bioorganic Med. Chem.*, 2007, **15**, 5283–5299.

- O. Abrahamsson, U. Ellervik, J. Eriksson-Bajtner,
 M. Jacobsson and K. Mani, *Carbohydr. Res.*, 2008, 343, 1473–1477.
- 10 M. Jacobsson, U. Ellervik, M. Belting and K. Mani, J. Med. Chem., 2006, 49, 1932–1938.
- 11 R. Johnsson, K. Mani and U. Ellervik, *Bioorg. Med. Chem. Lett.*, 2007, 17, 2338-2341.
- 12 A. Persson, E. Tykesson, G. Westergren-Thorsson, A. Malmström, U. Ellervik and K. Mani, *J. Biol. Chem.*, 2016, 291, 14871–14882.
- 13 U. Nilsson, R. Johnsson, L.-Å. Fransson, U. Ellervik and K. Mani, *Cancer Res.*, 2010, 70, 3771–3779.
- 14 A. Persson, U. Ellervik and K. Mani, Glycobiology, 2018, 28, 499–511.
- 15 A. Persson, A. Gomez Toledo, E. Vorontsov, W. Nasir, D. Willén, F. Noborn, U. Ellervik, K. Mani, J. Nilsson and G. Larson, J. Biol. Chem., 2018, 293, 10202–10219.
- 16 R. Almeida, S. B. Levery, U. Mandel, H. Kresse, T. Schwientek, E. P. Bennett and H. Clausen, *J. Biol. Chem.*, 1999, 274, 26165–26171.
- 17 Y. Tsutsui, B. Ramakrishnan and P. K. Qasba, *J. Biol. Chem.*, 2013, **288**, 31963–31970.
- 18 A. Siegbahn, S. Manner, A. Persson, E. Tykesson, K. Holmqvist, A. Ochocinska, J. Rönnols, A. Sundin, K. Mani, G. Westergren-Thorsson, G. Widmalm and U. Ellervik, *Chem. Sci.*, 2014, 5, 3501.
- K. Thorsheim, D. Willén, E. Tykesson, J. Ståhle, J. P. Praly,
 S. Vidal, M. T. Johnson, G. Widmalm, S. Manner and
 U. Ellervik, *Chem. Eur. J.*, 2017, 23, 18057–18065.
- 20 A. Ori, Front. Biosci., 2008, 1, 4309.
- 21 A. Siegbahn, K. Thorsheim, J. Ståhle, S. Manner, C. Hamark, A. Persson, E. Tykesson, K. Mani, G. Westergren-Thorsson, G. Widmalm and U. Ellervik, *Org. Biomol. Chem.*, 2015, 13, 3351–3362.
- 22 R. Johnsson, K. Mani, F. Cheng and U. Ellervik, *J. Org. Chem.*, 2006, **71**, 3444–3451.
- 23 V. M. Tran and B. Kuberan, *Bioconjug. Chem.*, 2014, 25, 262–268.
- 24 J. Qu, C. Kohl, M. Pottek and K. Müllen, *Angew. Chem., Int. Ed.*, 2004, **43**, 1528–1531.
- 25 V. de Halleux, W. Mamdouh, S. De Feyter, F. De Schryver, J. Levin and Y. H. Geerts, *J. Photochem. Photobiol.*, A, 2006, 178, 251–257.

- 26 V. Goyvaerts, S. Van Snick, L. D'Huys, R. Vitale, M. Helmer Lauer, S. Wang, V. Leen, W. Dehaen and J. Hofkens, *Chem. Commun.*, 2020, 56, 3317–3320.
- 27 M. M. Lee, Z. Gao and B. R. Peterson, *Angew. Chem., Int. Ed.*, 2017, **56**, 6927–6931.
- 28 R. K. Bhola, P. K. Das, S. Pradhan, K. Chakraborty, D. Mohapatra, P. Samal, P. C. Patra, S. S. Panda and S. K. Mishra, *J. Hematop.*, 2020, **13**, 13–24.
- 29 M. Naganbabu, L. A. Perkins, Y. Wang, J. Kurish, B. F. Schmidt and M. P. Bruchez, *Bioconjug. Chem.*, 2016, 27, 1525–1531.
- 30 W.-C. Sun, K. R. Gee and R. P. Haugland, *Bioorg. Med. Chem. Lett.*, 1998, 8, 3107–3110.
- 31 J. Kerkovius and F. Menard, Synthesis, 2016, 48, 1622-1629.
- 32 M. M. Lee and B. R. Peterson, *ACS Omega*, 2016, 1, 1266–1276.
- 33 M. M. Lee, An Improved Synthesis of the Pacific Blue Fluorophore and Fluorescence-based Studies of Receptor-Ligand Interactions, University of Kansas, 2016.
- 34 M. Saliba, N. Ramalanjaona, S. Gulberti, I. Bertin-Jung, A. Thomas, S. Dahbi, C. Lopin-Bon, J.-C. Jacquinet, C. Breton, M. Ouzzine and S. Fournel-Gigleux, *J. Biol. Chem.*, 2015, 290, 7658–7670.
- 35 S. Dahbi, J.-C. Jacquinet, I. Bertin-Jung, A. Robert, N. Ramalanjaona, S. Gulberti, S. Fournel-Gigleux and C. Lopin-Bon, *Org. Biomol. Chem.*, 2017, 15, 9653–9669.
- 36 É. Bozó, S. Boros, J. Kuszmann, E. Gács-Baitz and L. Párkányi, *Carbohydr. Res.*, 1998, **308**, 297–310.
- 37 R. L. Whistler and T. Van Es, *J. Org. Chem.*, 1963, **28**, 2303–2304.
- 38 Y. Collette, K. Ou, J. Pires, M. Baudry, G. Descotes, J. P. Praly and V. Barberousse, *Carbohydr. Res.*, 1999, **318**, 162–166.
- 39 K. Valkó, M. Plass, C. Bevan, D. Reynolds and M. Abraham, *J. Chromatogr. A*, 1998, 797, 41–55.
- 40 K. Valkó, J. Chromatogr. A, 2004, 1037, 299-310.
- 41 K. Thorsheim, S. Clementson, E. Tykesson, D. Bengtsson, D. Strand and U. Ellervik, *Tetrahedron Lett.*, 2017, 58, 3466–3469.
- 42 M. B. Jones, H. Teng, J. K. Rhee, N. Lahar, G. Baskaran and K. J. Yarema, *Biotechnol. Bioeng.*, 2004, **85**, 394–405.
- 43 L. D. Lavis, ACS Chem. Biol., 2008, 3, 203-206.
- 44 K. Prydz, Biomolecules, 2015, 5, 2003-2022.